Physician profile
Gabriel David Pujol Cuevas
NPI 1881147825
$2,853.33
in general payments reported to CMS, 2019-2025
10 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 90% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2022: $230 · 2023: $122 · 2024: $693 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,687 · Food and Beverage: $728 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,687.24 |
| Food and Beverage | $728.17 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,581.66 | 2025 | Trumatch, Matrixcombo |
| Medical Microinstruments, INC. | $520.75 | 2024 | Symani Surgical Systems |
| Genzyme Corporation | $297.97 | 2019-2022 | |
| Abbvie INC. | $140.68 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.06 | 2023 | Elaprase |
| Intersect Ent, INC. | $86.47 | 2019 | |
| Axogen | $31.84 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Cap |
| Janssen Pharmaceuticals, INC | $27.78 | 2019 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Keytruda |
| Depuy Synthes Sales INC. | $18.42 | 2025 | Matrixmandible |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Pujol Cuevas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.